Biovista announced today that it has entered into a drug repositioning collaboration with Astellas Pharma Inc. The collaboration is focused on identifying new indications for a number of undisclosed Astellas compounds using Biovista’s Clinical Outcome Search Space (COSS) technology.
“We look forward to working with the Drug Repurposing and Application Management at Astellas to compliment their work,” said Dr. Aris Persidis, President of Biovista. “Our very large scale systematic drug repositioning technology (the “Clinical Outcome Search Space – COSS(tm) offers the advantages of speed, comprehensiveness and depth of clinical outcome exploration, which we hope will help patients in need benefit even more from Astellas drugs,” he added.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at http://www.astellas.com/en .
Biovista is a privately held biotechnology company that finds novel uses for existing drugs, and profiles their side effects using their mechanism of action. Biovista is developing its own drug pipeline in multiple indications and is collaborating with the FDA on the prediction of adverse events, as well as with biopharmaceutical companies on indication expansion and de-risking of their portfolios (http://www.biovista.com).
For further information please contact: Dr. Aris Persidis, E: arispbiovista [dot] com